Financhill
Buy
62

AMED Quote, Financials, Valuation and Earnings

Last price:
$89.95
Seasonality move :
4.22%
Day range:
$89.34 - $90.10
52-week range:
$82.15 - $98.95
Dividend yield:
0%
P/E ratio:
35.70x
P/S ratio:
1.28x
P/B ratio:
2.57x
Volume:
2M
Avg. volume:
629.1K
1-year change:
-5.57%
Market cap:
$2.9B
Revenue:
$2.2B
EPS (TTM):
$2.52

Analysts' Opinion

  • Consensus Rating
    Amedisys has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 8 Hold ratings, and 1 Sell rating.
  • Price Target Upside
    According to analysts' consensus price target of $96.33, Amedisys has an estimated upside of 7.09% from its current price of $89.96.
  • Price Target Downside
    According to analysts, the lowest downside price target is $73.00 representing 18.85% downside risk from its current price of $89.96.

Fair Value

  • According to the consensus of 9 analysts, Amedisys has 7.09% upside to fair value with a price target of $96.33 per share.

AMED vs. S&P 500

  • Over the past 5 trading days, Amedisys has overperformed the S&P 500 by 6.66% suggesting its relative strength compared to the major market average is strong at this time.

Share Buyback

  • Amedisys does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Amedisys has grown year-over-year revenues for 4 quarters straight. In the most recent quarter Amedisys reported revenues of $587.7M.

Earnings Growth

  • Amedisys earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Amedisys reported earnings per share of $0.51.
Enterprise value:
3.1B
EV / Invested capital:
1.98x
Price / LTM sales:
1.28x
EV / EBIT:
18.81x
EV / Revenue:
1.35x
PEG ratio (5yr expected):
0.01x
EV / Free cash flow:
15.40x
Price / Operating cash flow:
14.56x
Enterprise value / EBITDA:
13.86x
Gross Profit (TTM):
$1B
Return On Assets:
3.97%
Net Income Margin (TTM):
3.57%
Return On Equity:
7.23%
Return On Invested Capital:
5.39%
Operating Margin:
8%
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Income Statement
Revenue $2.2B $2.2B $2.3B $556.2M $587.7M
Gross Profit $960M $986.4M $1B $244.6M $250.1M
Operating Income $185.7M $193.8M $208.9M $47.2M $47M
EBITDA $258.8M $140.4M $226.2M $60.5M $52.2M
Diluted EPS $3.71 $0.07 $2.52 $0.79 $0.51
Period Ending 2020-09-30 2021-09-30 2022-09-30 2023-09-30 2024-09-30
Balance Sheet
Current Assets $411.3M $432.9M $388.8M $467.2M $579.9M
Total Assets $1.6B $1.9B $2B $2B $2.1B
Current Liabilities $437.5M $454.3M $367.2M $468.1M $486M
Total Liabilities $845M $988.8M $912.5M $933.9M $938.7M
Total Equity $757.7M $948.8M $1.1B $1.1B $1.2B
Total Debt $311.3M $448M $456.1M $402.2M $381.9M
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Cash Flow Statement
Cash Flow Operations $97.6M $117.8M $211.7M -$9.8M $105.6M
Cash From Investing -$104.3M $35.2M -$9.1M -$1M -$2.4M
Cash From Financing -$90M -$90.4M -$51.1M -$6.3M -$15.1M
Free Cash Flow $91M $105.1M $203.5M -$11M $104M
AMED
Sector
Market Cap
$2.9B
$45.9M
Price % of 52-Week High
90.92%
46.95%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
-5.57%
-32.15%
Beta (5-Year)
0.726
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Technicals

8-day SMA
Buy
Level $85.59
200-day SMA
Sell
Level $94.01
Bollinger Bands (100)
Sell
Level 89.4 - 98.64
Chaikin Money Flow
Buy
Level 52.8M
20-day SMA
Buy
Level $86.16
Relative Strength Index (RSI14)
Buy
Level 61.30
ADX Line
Buy
Level 22.94
Williams %R
Sell
Level -1.761
50-day SMA
Sell
Level $90.80
MACD (12, 26)
Sell
Level -1.19
25-day Aroon Oscillator
Sell
Level -56
On Balance Volume
Neutral
Level 12.6M

Financial Scores

Buy
Altman Z-Score (Annual)
Level (3.7022)
Buy
CA Score (Annual)
Level (0.2422)
Buy
Beneish M-Score (Annual)
Level (-2.7857)
Buy
Momentum Score
Level (5)
Buy
Ohlson Score
Level (-6.8667)
Buy
Piotroski F Score (Annual)
Level (5)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (8)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Amedisys Inc is a healthcare services company in the United States. The company brings healthcare to the home through the provision of home healthcare services, hospice services, high acuity care segment, and personal care services. The Home Health Segment provides skilled nurses, therapists, and aids to patients' homes throughout the United States, Hospice segment operates many centers designed to provide comfort and support for terminally ill patients, Personal Care Segment provides individuals with assistance in their daily living activities and High acuity care segment can deliver the essential elements of inpatient hospital, SNF care, and palliative care to patients in their homes. A majority of the company's revenue is derived from the Home Health segment.

Stock Forecast FAQ

In the current month, AMED has received 0 Buy ratings 8 Hold ratings, and 1 Sell ratings. The AMED average analyst price target in the past 3 months is $96.33.

  • Where Will Amedisys Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Amedisys share price will rise to $96.33 per share over the next 12 months.

  • What Do Analysts Say About Amedisys?

    Analysts are divided on their view about Amedisys share price and where it will be in the next 12 months. The majority of analysts rate the stock a Sell. However, a smaller subset of analysts suggest that Amedisys is a Buy and believe this share price will drop from its current level to $101.00.

  • What Is Amedisys's Price Target?

    The price target for Amedisys over the next 1-year time period is forecast to be $96.33 according to 9 Wall Street analysts, 0 of them rate the stock a Buy, 1 rates the stock a Sell, and 8 analysts rate the stock a Hold.

  • Is AMED A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Amedisys is a Hold. 8 of 9 analysts rate the stock a Hold at this time.

  • How Can I Buy Shares Of AMED?

    You can purchase shares of Amedisys via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Amedisys shares.

  • What Is The Amedisys Share Price Today?

    Amedisys was last trading at $89.95 per share. This represents the most recent stock quote for Amedisys. Yesterday, Amedisys closed at $89.96 per share.

  • How To Buy Amedisys Stock Online?

    In order to purchase Amedisys stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Is Coinbase Stock Going Down?
Why Is Coinbase Stock Going Down?

Every way you look at it, Coinbase has had a…

Is Uber Stock a Buy on the Dip?
Is Uber Stock a Buy on the Dip?

Shares of Uber Technologies (NYSE:UBER) have been fading fast in…

Is AMD Stock an All-Time Buy?
Is AMD Stock an All-Time Buy?

Advanced Micro Devices (NASDAQ:AMD) is a high-growth AI stock that…

Stock Ideas

Buy
64
Is AAPL Stock a Buy?

Market Cap: $3.9T
P/E Ratio: 42x

Buy
52
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 115x

Buy
54
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 36x

Alerts

Sell
50
LMND alert for Dec 28

Lemonade [LMND] is down 10.69% over the past day.

Sell
50
TSLL alert for Dec 28

Direxion Daily TSLA Bull 2X Shares [TSLL] is down 9.92% over the past day.

Buy
63
SMLR alert for Dec 28

Semler Scientific [SMLR] is down 9.65% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock